Mbal Za Zhensko Zdrave Nadezhda OOD
- Address
- lock Available on a paid plan
MBAL Za Zhensko Zdrave Nadezhda OOD - Oncology Research Center
MBAL Za Zhensko Zdrave Nadezhda OOD is a specialized clinical research facility with extensive expertise in oncological studies, particularly focused on advanced breast cancer therapies and solid tumor investigations. The center demonstrates significant capabilities in evaluating novel immunotherapy combinations and targeted therapeutic agents across multiple cancer types, with a strong emphasis on precision medicine approaches.
- HER2-positive and hormone receptor-positive breast cancer, including early-stage and advanced/metastatic disease with novel antibody-drug conjugates and CDK4/6 inhibitors
- Triple-negative breast cancer and hormone receptor-low subtypes utilizing neoadjuvant and adjuvant immunotherapy protocols
- Non-small cell lung cancer investigating PD-1/PD-L1 inhibitor combinations and second/third-line therapeutic strategies
- Colorectal cancer with BRAF V600E mutations and other solid tumors with targeted molecular therapies
The institution's research portfolio reflects deep involvement in Phase III randomized controlled trials evaluating cutting-edge treatments including immunotherapy agents, targeted kinase inhibitors, and antibody-drug conjugates. The center's participation in studies examining PIK3CA-mutated cancers and biomarker-driven therapeutic selection underscores its commitment to advancing personalized cancer care and contributing to the development of next-generation oncology treatments.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 5 therapeutic areas and 15 of 71 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 68 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 8 by active trials.
- 1Pfizer Inc.4active
lock +7 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Pfizer Inc.7trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Mbal Za Zhensko Zdrave Nadezhda OOD
lock Showing 1 of 23 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Visugromab in Patients with Cancer-associated Cachexia | CatalYm GmbH | Phase IV | Recruiting | Mar 2026 | — |
IMP list
lock Showing 1 of 71 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 6 | Unknown | 2023-11-13 | 2025-07-18 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.